Compare FATE & BWG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FATE | BWG |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.6M | 139.7M |
| IPO Year | 2013 | N/A |
| Metric | FATE | BWG |
|---|---|---|
| Price | $1.34 | $7.97 |
| Analyst Decision | Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.10 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 92.5K |
| Earning Date | 05-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.37% |
| EPS Growth | ★ 29.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,646,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.05 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.66 | $7.46 |
| 52 Week High | $1.94 | $8.94 |
| Indicator | FATE | BWG |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 20.18 |
| Support Level | $0.96 | N/A |
| Resistance Level | $1.35 | $8.58 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.02 | -0.05 |
| Stochastic Oscillator | 20.43 | 8.00 |
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
BrandywineGLOBAL - Global Income Opportunities Fund Inc is a non-diversified, closed-end management investment company. The primary investment objective is to provide current income. The secondary investment objective is capital appreciation. The Fund seeks to achieve its investment objectives by investing, under normal market conditions, at least 80% of its assets in world-wide fixed-income securities.